5 Biotech Stocks Undervalued By EPS Trends

Abbott Laboratories Amgen Arena Pharmaceuticals AstraZeneca Bayer Biogen Idec biotech Boston Scientific Bristol-Myers Squibb cancer Celgene China Dendreon diabetes earnings Eli Lilly Europe FDA generics Genzyme GSK hepatitis C investors JNJ lawsuits layoffs M&A Management Medtronic Merck Novartis obesity patents Pfizer prostate cancer Roche Sanofi Teva Pharmaceuticals vaccines Vivus